Plus   Neg

Agilent Gets FDA Approval For PD-L1 Companion Diagnostic On Dako Omnis

Agilent Technologies Inc. (A) said that the U.S. Food and Drug Administration has
approved the company's PD-L1 IHC 22C3 pharmDx as a companion diagnostic or CDx
to identify patients with non-small cell lung cancer who are appropriate for
first-line monotherapy with KEYTRUDA or pembrolizumab on the Dako Omnis platform.

Dako Omnis is Agilent's fully automated, walk-away solution for staining
tumor samples that provides a flexible, high-throughput diagnostic service
integrated into the core of the laboratory workflow.

Lung cancer is the leading cause of cancer-related mortality in the United
States, with an estimated incidence of 142,000 deaths in 2019 alone.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
U.S. Court grants Tiffany's motion to expedite lawsuit against LVMH Moët Hennessy-Louis Vuitton. However, the court has not agreed to Tiffany request for trial before November 24. Biotech company Illumina agreed to buy healthcare company GRAIL, Inc. in a cash and stock deal valued at $8 billion. This includes $3.5 billion in cash and $4.5 billion in shares of Illumina common stock. GRAIL focuses on multi-cancer early detection from blood. It is in the process of developing the technology and providing clinical data required to launch the Galleri multi-cancer screening test. Oracle and Walmart have tentatively agreed to acquire 20% of the newly formed TikTok Global business, the companies said in a statement.
Follow RTT